Table of Content

1 Report Overview
1.1 Dermatomycoses Drug Definition
1.2 Market by Type
1.2.1 Global Dermatomycoses Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 BB-2603
1.2.3 Clotrimazole
1.2.4 Dapaconazole
1.2.5 Others
1.3 Market Segment by Application
1.3.1 Global Dermatomycoses Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Dermatomycoses Drug Sales
2.1 Global Dermatomycoses Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Dermatomycoses Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Dermatomycoses Drug Revenue by Region
2.3.1 Global Dermatomycoses Drug Revenue by Region (2018-2024)
2.3.2 Global Dermatomycoses Drug Revenue by Region (2024-2034)
2.4 Global Dermatomycoses Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Dermatomycoses Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Dermatomycoses Drug Sales Quantity by Region
2.6.1 Global Dermatomycoses Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Dermatomycoses Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Dermatomycoses Drug Sales Quantity by Manufacturers
3.1.1 Global Dermatomycoses Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Dermatomycoses Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Dermatomycoses Drug Sales in 2022
3.2 Global Dermatomycoses Drug Revenue by Manufacturers
3.2.1 Global Dermatomycoses Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Dermatomycoses Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Dermatomycoses Drug Revenue in 2022
3.3 Global Dermatomycoses Drug Sales Price by Manufacturers
3.4 Global Key Players of Dermatomycoses Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Dermatomycoses Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Dermatomycoses Drug, Product Offered and Application
3.8 Global Key Manufacturers of Dermatomycoses Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Dermatomycoses Drug Sales Quantity by Type
4.1.1 Global Dermatomycoses Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Dermatomycoses Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Dermatomycoses Drug Revenue by Type
4.2.1 Global Dermatomycoses Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Dermatomycoses Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
4.3 Global Dermatomycoses Drug Price by Type
4.3.1 Global Dermatomycoses Drug Price by Type (2018-2024)
4.3.2 Global Dermatomycoses Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Dermatomycoses Drug Sales Quantity by Application
5.1.1 Global Dermatomycoses Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Dermatomycoses Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Dermatomycoses Drug Revenue by Application
5.2.1 Global Dermatomycoses Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Dermatomycoses Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
5.3 Global Dermatomycoses Drug Price by Application
5.3.1 Global Dermatomycoses Drug Price by Application (2018-2024)
5.3.2 Global Dermatomycoses Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Dermatomycoses Drug Sales by Company
6.1.1 North America Dermatomycoses Drug Revenue by Company (2018-2024)
6.1.2 North America Dermatomycoses Drug Sales Quantity by Company (2018-2024)
6.2 North America Dermatomycoses Drug Market Size by Type
6.2.1 North America Dermatomycoses Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Dermatomycoses Drug Revenue by Type (2018-2034)
6.3 North America Dermatomycoses Drug Market Size by Application
6.3.1 North America Dermatomycoses Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Dermatomycoses Drug Revenue by Application (2018-2034)
6.4 North America Dermatomycoses Drug Market Size by Country
6.4.1 North America Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Dermatomycoses Drug Revenue by Country (2018-2034)
6.4.3 North America Dermatomycoses Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Dermatomycoses Drug Sales by Company
7.1.1 Europe Dermatomycoses Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Dermatomycoses Drug Revenue by Company (2018-2024)
7.2 Europe Dermatomycoses Drug Market Size by Type
7.2.1 Europe Dermatomycoses Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Dermatomycoses Drug Revenue by Type (2018-2034)
7.3 Europe Dermatomycoses Drug Market Size by Application
7.3.1 Europe Dermatomycoses Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Dermatomycoses Drug Revenue by Application (2018-2034)
7.4 Europe Dermatomycoses Drug Market Size by Country
7.4.1 Europe Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Dermatomycoses Drug Revenue by Country (2018-2034)
7.4.3 Europe Dermatomycoses Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Dermatomycoses Drug Sales by Company
8.1.1 China Dermatomycoses Drug Sales Quantity by Company (2018-2024)
8.1.2 China Dermatomycoses Drug Revenue by Company (2018-2024)
8.2 China Dermatomycoses Drug Market Size by Type
8.2.1 China Dermatomycoses Drug Sales Quantity by Type (2018-2034)
8.2.2 China Dermatomycoses Drug Revenue by Type (2018-2034)
8.3 China Dermatomycoses Drug Market Size by Application
8.3.1 China Dermatomycoses Drug Sales Quantity by Application (2018-2034)
8.3.2 China Dermatomycoses Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Dermatomycoses Drug Sales by Company
9.1.1 APAC Dermatomycoses Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Dermatomycoses Drug Revenue by Company (2018-2024)
9.2 APAC Dermatomycoses Drug Market Size by Type
9.2.1 APAC Dermatomycoses Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Dermatomycoses Drug Revenue by Type (2018-2034)
9.3 APAC Dermatomycoses Drug Market Size by Application
9.3.1 APAC Dermatomycoses Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Dermatomycoses Drug Revenue by Application (2018-2034)
9.4 APAC Dermatomycoses Drug Market Size by Region
9.4.1 APAC Dermatomycoses Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Dermatomycoses Drug Revenue by Region (2018-2034)
9.4.3 APAC Dermatomycoses Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Dermatomycoses Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Dermatomycoses Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Dermatomycoses Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Dermatomycoses Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Anacor Pharmaceuticals Inc
11.1.1 Anacor Pharmaceuticals Inc Company Information
11.1.2 Anacor Pharmaceuticals Inc Overview
11.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Products and Services
11.1.5 Anacor Pharmaceuticals Inc Dermatomycoses Drug SWOT Analysis
11.1.6 Anacor Pharmaceuticals Inc Recent Developments
11.2 Biolab Farmaceutica Ltda
11.2.1 Biolab Farmaceutica Ltda Company Information
11.2.2 Biolab Farmaceutica Ltda Overview
11.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Products and Services
11.2.5 Biolab Farmaceutica Ltda Dermatomycoses Drug SWOT Analysis
11.2.6 Biolab Farmaceutica Ltda Recent Developments
11.3 Blueberry Therapeutics Ltd
11.3.1 Blueberry Therapeutics Ltd Company Information
11.3.2 Blueberry Therapeutics Ltd Overview
11.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Products and Services
11.3.5 Blueberry Therapeutics Ltd Dermatomycoses Drug SWOT Analysis
11.3.6 Blueberry Therapeutics Ltd Recent Developments
11.4 Daewoong Pharmaceutical Co Ltd
11.4.1 Daewoong Pharmaceutical Co Ltd Company Information
11.4.2 Daewoong Pharmaceutical Co Ltd Overview
11.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Products and Services
11.4.5 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug SWOT Analysis
11.4.6 Daewoong Pharmaceutical Co Ltd Recent Developments
11.5 Dermala Inc
11.5.1 Dermala Inc Company Information
11.5.2 Dermala Inc Overview
11.5.3 Dermala Inc Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Dermala Inc Dermatomycoses Drug Products and Services
11.5.5 Dermala Inc Dermatomycoses Drug SWOT Analysis
11.5.6 Dermala Inc Recent Developments
11.6 Helix BioMedix Inc
11.6.1 Helix BioMedix Inc Company Information
11.6.2 Helix BioMedix Inc Overview
11.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Helix BioMedix Inc Dermatomycoses Drug Products and Services
11.6.5 Helix BioMedix Inc Dermatomycoses Drug SWOT Analysis
11.6.6 Helix BioMedix Inc Recent Developments
11.7 Novan Inc
11.7.1 Novan Inc Company Information
11.7.2 Novan Inc Overview
11.7.3 Novan Inc Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Novan Inc Dermatomycoses Drug Products and Services
11.7.5 Novan Inc Dermatomycoses Drug SWOT Analysis
11.7.6 Novan Inc Recent Developments
11.8 Sol-Gel Technologies Ltd
11.8.1 Sol-Gel Technologies Ltd Company Information
11.8.2 Sol-Gel Technologies Ltd Overview
11.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Products and Services
11.8.5 Sol-Gel Technologies Ltd Dermatomycoses Drug SWOT Analysis
11.8.6 Sol-Gel Technologies Ltd Recent Developments
11.9 TGV-Laboratories
11.9.1 TGV-Laboratories Company Information
11.9.2 TGV-Laboratories Overview
11.9.3 TGV-Laboratories Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 TGV-Laboratories Dermatomycoses Drug Products and Services
11.9.5 TGV-Laboratories Dermatomycoses Drug SWOT Analysis
11.9.6 TGV-Laboratories Recent Developments
11.10 Viamet Pharmaceuticals Inc
11.10.1 Viamet Pharmaceuticals Inc Company Information
11.10.2 Viamet Pharmaceuticals Inc Overview
11.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Products and Services
11.10.5 Viamet Pharmaceuticals Inc Dermatomycoses Drug SWOT Analysis
11.10.6 Viamet Pharmaceuticals Inc Recent Developments
11.11 Vyome Biosciences Pvt Ltd
11.11.1 Vyome Biosciences Pvt Ltd Company Information
11.11.2 Vyome Biosciences Pvt Ltd Overview
11.11.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Products and Services
11.11.5 Vyome Biosciences Pvt Ltd Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Dermatomycoses Drug Value Chain Analysis
12.2 Dermatomycoses Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dermatomycoses Drug Production Mode & Process
12.4 Dermatomycoses Drug Sales and Marketing
12.4.1 Dermatomycoses Drug Sales Channels
12.4.2 Dermatomycoses Drug Distributors
12.5 Dermatomycoses Drug Customers
13 Market Dynamics
13.1 Dermatomycoses Drug Industry Trends
13.2 Dermatomycoses Drug Market Drivers
13.3 Dermatomycoses Drug Market Challenges
13.4 Dermatomycoses Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Dermatomycoses Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of BB-2603
Table 3. Major Manufacturers of Clotrimazole
Table 4. Major Manufacturers of Dapaconazole
Table 5. Major Manufacturers of Others
Table 6. Global Dermatomycoses Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Dermatomycoses Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Dermatomycoses Drug Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Dermatomycoses Drug Revenue Market Share by Region (2018-2024)
Table 10. Global Dermatomycoses Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Dermatomycoses Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Dermatomycoses Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Dermatomycoses Drug Sales by Region (2018-2024) & (K Units)
Table 14. Global Dermatomycoses Drug Sales Market Share by Region (2018-2024)
Table 15. Global Dermatomycoses Drug Sales by Region (2024-2034) & (K Units)
Table 16. Global Dermatomycoses Drug Sales Market Share by Region (2024-2034)
Table 17. Global Dermatomycoses Drug Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Dermatomycoses Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Dermatomycoses Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Dermatomycoses Drug Revenue Share by Manufacturers (2018-2024)
Table 21. Global Dermatomycoses Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Dermatomycoses Drug, Industry Ranking, 2021 VS 2022
Table 23. Global Dermatomycoses Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Dermatomycoses Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dermatomycoses Drug as of 2022)
Table 25. Global Key Manufacturers of Dermatomycoses Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Dermatomycoses Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Dermatomycoses Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Dermatomycoses Drug Sales Quantity Share by Type (2018-2024)
Table 32. Global Dermatomycoses Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Dermatomycoses Drug Revenue Share by Type (2018-2024)
Table 36. Global Dermatomycoses Drug Revenue Share by Type (2024-2034)
Table 37. Dermatomycoses Drug Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Dermatomycoses Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Dermatomycoses Drug Sales Quantity Share by Application (2018-2024)
Table 42. Global Dermatomycoses Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Dermatomycoses Drug Revenue Share by Application (2018-2024)
Table 46. Global Dermatomycoses Drug Revenue Share by Application (2024-2034)
Table 47. Dermatomycoses Drug Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Dermatomycoses Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Dermatomycoses Drug Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Dermatomycoses Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Dermatomycoses Drug Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Dermatomycoses Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Dermatomycoses Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Dermatomycoses Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Dermatomycoses Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Dermatomycoses Drug Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Dermatomycoses Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Dermatomycoses Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Dermatomycoses Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Dermatomycoses Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Dermatomycoses Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Dermatomycoses Drug Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Dermatomycoses Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Dermatomycoses Drug Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Dermatomycoses Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Dermatomycoses Drug Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Dermatomycoses Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Dermatomycoses Drug Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Dermatomycoses Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Dermatomycoses Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Anacor Pharmaceuticals Inc Company Information
Table 120. Anacor Pharmaceuticals Inc Description and Overview
Table 121. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product and Services
Table 123. Anacor Pharmaceuticals Inc Dermatomycoses Drug SWOT Analysis
Table 124. Anacor Pharmaceuticals Inc Recent Developments
Table 125. Biolab Farmaceutica Ltda Company Information
Table 126. Biolab Farmaceutica Ltda Description and Overview
Table 127. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Biolab Farmaceutica Ltda Dermatomycoses Drug Product and Services
Table 129. Biolab Farmaceutica Ltda Dermatomycoses Drug SWOT Analysis
Table 130. Biolab Farmaceutica Ltda Recent Developments
Table 131. Blueberry Therapeutics Ltd Company Information
Table 132. Blueberry Therapeutics Ltd Description and Overview
Table 133. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Blueberry Therapeutics Ltd Dermatomycoses Drug Product and Services
Table 135. Blueberry Therapeutics Ltd Dermatomycoses Drug SWOT Analysis
Table 136. Blueberry Therapeutics Ltd Recent Developments
Table 137. Daewoong Pharmaceutical Co Ltd Company Information
Table 138. Daewoong Pharmaceutical Co Ltd Description and Overview
Table 139. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product and Services
Table 141. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug SWOT Analysis
Table 142. Daewoong Pharmaceutical Co Ltd Recent Developments
Table 143. Dermala Inc Company Information
Table 144. Dermala Inc Description and Overview
Table 145. Dermala Inc Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 146. Dermala Inc Dermatomycoses Drug Product and Services
Table 147. Dermala Inc Dermatomycoses Drug SWOT Analysis
Table 148. Dermala Inc Recent Developments
Table 149. Helix BioMedix Inc Company Information
Table 150. Helix BioMedix Inc Description and Overview
Table 151. Helix BioMedix Inc Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 152. Helix BioMedix Inc Dermatomycoses Drug Product and Services
Table 153. Helix BioMedix Inc Dermatomycoses Drug SWOT Analysis
Table 154. Helix BioMedix Inc Recent Developments
Table 155. Novan Inc Company Information
Table 156. Novan Inc Description and Overview
Table 157. Novan Inc Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 158. Novan Inc Dermatomycoses Drug Product and Services
Table 159. Novan Inc Dermatomycoses Drug SWOT Analysis
Table 160. Novan Inc Recent Developments
Table 161. Sol-Gel Technologies Ltd Company Information
Table 162. Sol-Gel Technologies Ltd Description and Overview
Table 163. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 164. Sol-Gel Technologies Ltd Dermatomycoses Drug Product and Services
Table 165. Sol-Gel Technologies Ltd Dermatomycoses Drug SWOT Analysis
Table 166. Sol-Gel Technologies Ltd Recent Developments
Table 167. TGV-Laboratories Company Information
Table 168. TGV-Laboratories Description and Overview
Table 169. TGV-Laboratories Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 170. TGV-Laboratories Dermatomycoses Drug Product and Services
Table 171. TGV-Laboratories Dermatomycoses Drug SWOT Analysis
Table 172. TGV-Laboratories Recent Developments
Table 173. Viamet Pharmaceuticals Inc Company Information
Table 174. Viamet Pharmaceuticals Inc Description and Overview
Table 175. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 176. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product and Services
Table 177. Viamet Pharmaceuticals Inc Dermatomycoses Drug SWOT Analysis
Table 178. Viamet Pharmaceuticals Inc Recent Developments
Table 179. Vyome Biosciences Pvt Ltd Company Information
Table 180. Vyome Biosciences Pvt Ltd Description and Overview
Table 181. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 182. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product and Services
Table 183. Vyome Biosciences Pvt Ltd Recent Developments
Table 184. Key Raw Materials Lists
Table 185. Raw Materials Key Suppliers Lists
Table 186. Dermatomycoses Drug Distributors List
Table 187. Dermatomycoses Drug Customers List
Table 188. Dermatomycoses Drug Market Trends
Table 189. Dermatomycoses Drug Market Drivers
Table 190. Dermatomycoses Drug Market Challenges
Table 191. Dermatomycoses Drug Market Restraints
Table 192. Research Programs/Design for This Report
Table 193. Key Data Information from Secondary Sources
Table 194. Key Data Information from Primary Sources
List of Figures
Figure 1. Dermatomycoses Drug Product Picture
Figure 2. Global Dermatomycoses Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Dermatomycoses Drug Market Share by Type in 2022 & 2034
Figure 4. BB-2603 Product Picture
Figure 5. Clotrimazole Product Picture
Figure 6. Dapaconazole Product Picture
Figure 7. Others Product Picture
Figure 8. Global Dermatomycoses Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Dermatomycoses Drug Market Share by Application in 2022 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Dermatomycoses Drug Report Years Considered
Figure 14. Global Dermatomycoses Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Dermatomycoses Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Dermatomycoses Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Dermatomycoses Drug Sales Quantity 2018-2034 (K Units)
Figure 18. Global Dermatomycoses Drug Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Dermatomycoses Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Dermatomycoses Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Dermatomycoses Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Dermatomycoses Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Dermatomycoses Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Dermatomycoses Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Dermatomycoses Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Dermatomycoses Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Dermatomycoses Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Dermatomycoses Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Dermatomycoses Drug Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Dermatomycoses Drug Revenue in 2022
Figure 32. Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Dermatomycoses Drug Revenue Market Share by Company in 2022
Figure 38. North America Dermatomycoses Drug Sales Quantity Market Share by Company in 2022
Figure 39. North America Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Dermatomycoses Drug Revenue Share by Country (2018-2034)
Figure 44. North America Dermatomycoses Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Dermatomycoses Drug Sales Quantity Market Share by Company in 2022
Figure 48. Europe Dermatomycoses Drug Revenue Market Share by Company in 2022
Figure 49. Europe Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Dermatomycoses Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Dermatomycoses Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Dermatomycoses Drug Sales Quantity Market Share by Company in 2022
Figure 61. China Dermatomycoses Drug Revenue Market Share by Company in 2022
Figure 62. China Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Dermatomycoses Drug Sales Quantity Market Share by Company in 2022
Figure 67. APAC Dermatomycoses Drug Revenue Market Share by Company in 2022
Figure 68. APAC Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Dermatomycoses Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Dermatomycoses Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Dermatomycoses Drug Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Dermatomycoses Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Dermatomycoses Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Dermatomycoses Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Dermatomycoses Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Dermatomycoses Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Dermatomycoses Drug Value Chain
Figure 93. Dermatomycoses Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed